Coagulation Factor IX (Recombinant) comment watch save
BreastfeedingPediatric

  • TRADE NAMES: Alprolix (Biogen Idec); BeneFIX (Wyeth); Idelvion (CSL Behring); Ixinity; rFIX; Rixubis (Baxter)
  • INDICATIONS: Treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency)
  • CLASS: Factor IX stimulant
  • HALF-LIFE: variable e.g. 13–43 hours (Xinity); 26 hours (Rixubis); 90–93 hours (Idelvion)
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top